Papers: 10.1371/journal.pone.0220142

https://doi.org/10.1371/journal.pone.0220142

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

Cited by: 7
Author(s): Saara Huoponen, Kalle Aaltonen, Jaana Viikinkoski, Juha Rutanen, Heikki Relas, Kirsi Taimen, Kari Puolakka, Dan Nordström, Marja Blom
Published: about 7 years ago

Software Mentions 1